Stockscreener 앱 받기
2.41
2.82%
-0.07
시간 외 거래:
2.43
0.02
+0.83%
전일 마감가:
$2.48
열려 있는:
$2.55
하루 거래량:
4.65M
Relative Volume:
2.34
시가총액:
$486.82M
수익:
$314.00K
순이익/손실:
$-40.23M
주가수익비율:
-8.6071
EPS:
-0.28
순현금흐름:
$-84.71M
1주 성능:
+4.33%
1개월 성능:
+74.64%
6개월 성능:
+54.49%
1년 성능:
+62.84%
1일 변동 폭
$2.37
$2.55
1주일 범위
$2.2402
$2.64
52주 변동 폭
$1.03
$2.64
Atai Life Sciences N V Stock (ATAI) Company Profile
명칭
Atai Life Sciences N V
전화
49 89 2153 9035
주소
WALLSTRASSE 16, BERLIN
ATAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
2.41 | 486.82M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Life Sciences N V 주식(ATAI)의 최신 뉴스
Lucid Capital Markets initiates coverage on atai Life Sciences stock - Investing.com India
ATAI Gains Buy Rating and Price Target from Lucid Capital | ATAI Stock News - GuruFocus
ATAI and Beckley Psytech Set to Merge in Strategic All-Share Dea - GuruFocus
Regeneron makes obesity push; Atai, Alto ink brain drug deals - Yahoo Finance
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders - PR Newswire
H.C. Wainwright maintains buy rating on atai Life Sciences stock By Investing.com - Investing.com India
H.C. Wainwright maintains buy rating on atai Life Sciences stock - Investing.com
Atai Life Sciences Merges With Beckley Psytech In Major Shakeup - Finimize
atai Life Sciences and Beckley Psytech merging - Seeking Alpha
Atai Life Sciences, Beckley Psytech to Merge in All-Stock Transaction - marketscreener.com
Transcript : Atai Life Sciences N.V., Beckley Psytech LimitedM&A Call - marketscreener.com
Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley - Bloomberg
ATAI and Beckley Psytech Plan Merger in Strategic All-Share Deal | ATAI Stock News - GuruFocus
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - Yahoo Finance
Beckley Psytech & atai Life Sciences to combine expertise in pivotal merger - Mugglehead Magazine
atai Life Sciences to Participate in Upcoming Investor Conferences - Yahoo
2 ‘Strong Buy’ Psychedelic Stocks To Scoop Up ASAP - Barchart.com
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors - Benzinga
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know - Nasdaq
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? - sharewise
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance
atai Life Sciences holds annual general meeting - Investing.com Australia
atai Life Sciences holds annual general meeting By Investing.com - Investing.com India
ATAI Life Sciences Approves Key Governance Changes - TipRanks
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies - Yahoo Finance
ATAI Life Sciences Sees Significant Rise in Borrow Rate | ATAI S - GuruFocus
ATAI Stock Poised for Growth After Positive Phase 2a Data on BPL - GuruFocus
ATAI Stock Poised for Growth After Positive Phase 2a Data on BPL-003 | ATAI Stock News - GuruFocus
ATAI Life Sciences (ATAI) Shows Encouraging Mid-Stage Trial Resu - GuruFocus
atai Life Sciences reports positive data from mid-stage depression trial - Seeking Alpha
ATAI Reiterates a 'Buy' Rating with a Price Target of $10 | ATAI Stock News - GuruFocus
Atai Life Sciences Reports Positive Phase 2a Results for Treatment-Resistant Depression Drug - marketscreener.com
ATAI Life Sciences Reports Promising Findings from Depression Study | ATAI Stock News - GuruFocus
atai reports positive phase 2a results for depression treatment By Investing.com - Investing.com UK
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression - Yahoo Finance
How Do Things Look For ATAI Life Sciences N.V (NASDAQ: ATAI) In The Short-Term? - Stocksregister
Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt - simplywall.st
ATAI Explores Psychedelic Solutions for Veterans' Mental Health - GuruFocus
ATAI Explores Psychedelic Solutions for Veterans' Mental Health | ATAI Stock News - GuruFocus
Atai Life Sciences: Progress in Psychedelic Mental Health Treatments - TipRanks
Will Atai Get A New Lease Of Life? - RTTNews
Atai Life Sciences Reports First Quarter 2025 Financial Results - marketscreener.com
ATAI Reports Significant First Quarter Revenue Growth | ATAI Sto - GuruFocus
ATAI Sees Financial Boost with Cash Reserves Rise | ATAI Stock N - GuruFocus
ATAI Reports Significant First Quarter Revenue Growth | ATAI Stock News - GuruFocus
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - The Manila Times
Certain Restricted stock units of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Options of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Atai Life Sciences N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.51%
자본화:
|
볼륨(24시간):